Organ-on-a-Chip studies are being hailed as the key to faster, more accurate drug development and precision medicine. Join this webinar for a walkthrough of the most advanced commercial Organ-on-a-Chip devices.
Organ-on-Chip systems – including academic prototypes and more recently commercial devices – are installed in industry and academic labs worldwide. They are being evaluated by the FDA for use in drug development and regulatory studies.
In March 2018, Nature Scientific Reports covered the final milestone of a $26M DARPA program which successfully connected engineered tissues from 10 organs, accurately replicating human organ interactions for weeks at a time and allowing researchers to measure the effects of drugs on different parts of the body.
And in a February 2018 article in Nature Communications, scientists at Imperial College London demonstrated how organ-on-a-chip technology has been used to study viral infections, in this case Hepatitis B infection of a liver-on-a-chip. This approach aims to provide a better understanding of disease and improve the development of new treatments.
Organ-on-Chip technology has also featured recently in BioCentury, The Economist, TechCrunch, the BBC and numerous specialist scientific and technology media outlets.
Join this webinar to discover:
- How to run Organ-on-a-Chip studies in your own lab to enhance research
- Walkthrough of an Organ-on-Chip workflow: lab set-up, seeding and culturing cells, dosing, sampling and analysis
- Practical advice and resources to support successful Organ-on-a-Chip studies: equipment, cell selection, protocols, assays and data analysis
Dr. Emma Sceats, CEO, CN Bio Innovations
Dr. Emma Sceats is CEO of CN Bio Innovations, which produces organs-on-a-chip devices for drug discovery and research. At CN Bio, Dr. Sceats has licensed technology from the Massachusetts Institute of Technology and other leading institutions, including Vanderbilt and the University of Oxford. Her team has developed the MIT technology into a commercial plug and play organ-on-a-chip system which enables researchers to choose the organ they wish to work with. Emma has steered CN Bio’s commercial negotiations in over 25 successful pharmaceutical and biotech deals. She was a Presidential Scholar at MIT and a holds a doctorate in chemistry from Oxford.Message Presenter
Dr. David Hughes, CTO, CN Bio Innovations
Dr. Hughes joined CN Bio Innovations in 2010 as Head of Engineering and was promoted to Chief Technical Officer in July 2014. He is responsible for managing the technical programs with the company’s academic and industrial partners. Dr. Hughes is Principal Investigator on the company’s $26Mi US Defence Advanced Research Projects Agency (DARPA) contract under which CN Bio has co-developed a 10 organ human body-on-a-chip. He leads a €4Mi EU FP7 program aimed at developing stem cell derived models of human liver. Before joining CN Bio, he worked in manufacturing and research and development at GlaxoSmithKline. Dr Hughes graduated from the University of Oxford with a Masters in Engineering Science and Doctorate in Chemical Engineering.Message Presenter
Who Should Attend?
Senior professionals from pharmaceutical and biotechnology companies, CROs, academia and research institutes, including these functions:
- Cell Biologists
- Preclinical / Translational Development Managers
- Research & Development Managers
- Senior Scientists
- Pre-market Stewardship
- Principal Investigators
- Project Managers
- Therapeutic Area Mangers
- Chief Scientific Officers / Chief Technology Officers
- Post-Doctoral Fellows
What You Will Learn
- How to run organ-on-a-chip studies in your own lab to enhance research
- Walkthrough of an organ-on-chip workflow: lab set-up, seeding and culturing cells, dosing, sampling and analysis
- Practical advice and resources to support successful organ-on-a-chip studies: equipment, cell selection, protocols, assays and data analysis
CN Bio Innovations
CN Bio Innovations develops devices that boost the precision and speed of biological research. By predicting the effects chemical and biological substances will have on human organs, researchers can fast-track improvements in healthcare.
In the past 4 years CN Bio has worked on more than 25 projects with pharmaceutical partners, using the company’s Organs-on-Chips and related microfluidic devices to gather precise, human-relevant data.
CN Bio is also collaborating with the US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research. FDA and CN Bio are using CN Bio’s Organs-on-Chips as a platform for drug development and regulatory evaluation, including safety testing prior to new drugs entering clinical trials.
CN Bio is backed by prestigious grant awards from sponsors including the US Department of Defense and Innovate UK. Spun out from the University of Oxford, the company is collaborating with and developing intellectual property from the Massachusetts Institute of Technology and Vanderbilt University.
In 2017, cell-culture technology developed at Vanderbilt and being commercialized by CN Bio won a R&D 100 Award, being recognized as one of the most technologically significant products introduced into market that year.